AAAAAA

   
Results: 1-12 |
Results: 12
Targeting of doxorubicin to ES-2 human ovarian cancers in nude mice by linking to an analog of luteinizing hormone-releasing hormone improves its effectiveness
Authors: Arencibia, JM Schally, AV Krupa, M Bajo, AM Nagy, A Szepeshazi, K Plonowski, A
Citation: Jm. Arencibia et al., Targeting of doxorubicin to ES-2 human ovarian cancers in nude mice by linking to an analog of luteinizing hormone-releasing hormone improves its effectiveness, INT J ONCOL, 19(3), 2001, pp. 571-577
In vitro targeting of a cytotoxic analog of luteinizing hormone-releasing hormone AN-207 to ES-2 human ovarian cancer cells as demonstrated by microsatellite analyses
Authors: Arencibia, JM Schally, AV Halmos, G Nagy, A Kiaris, H
Citation: Jm. Arencibia et al., In vitro targeting of a cytotoxic analog of luteinizing hormone-releasing hormone AN-207 to ES-2 human ovarian cancer cells as demonstrated by microsatellite analyses, ANTI-CANC D, 12(1), 2001, pp. 71-78
Inhibition of growth of ES-2 human ovarian cancers by bombesin antagonist RC-3095, and luteinizing hormone-releasing hormone antagonist Cetrorelix
Authors: Chatzistamou, I Schally, AV Szepeshazi, K Groot, K Hebert, F Arencibia, JM
Citation: I. Chatzistamou et al., Inhibition of growth of ES-2 human ovarian cancers by bombesin antagonist RC-3095, and luteinizing hormone-releasing hormone antagonist Cetrorelix, CANCER LETT, 171(1), 2001, pp. 37-45
Inhibition of the UCI-107 human ovarian carcinoma cell line by a targeted cytotoxic analog of somatostatin, AN-238
Authors: Plonowski, A Schally, AV Koppan, M Nagy, A Arencibia, JM Csernus, B Halmos, G
Citation: A. Plonowski et al., Inhibition of the UCI-107 human ovarian carcinoma cell line by a targeted cytotoxic analog of somatostatin, AN-238, CANCER, 92(5), 2001, pp. 1168-1176
Luteinizing hormone-releasing hormone as an autocrine growth factor in ES-2 ovarian cancer cell line
Authors: Arencibia, JM Schally, AV
Citation: Jm. Arencibia et Av. Schally, Luteinizing hormone-releasing hormone as an autocrine growth factor in ES-2 ovarian cancer cell line, INT J ONCOL, 16(5), 2000, pp. 1009-1013
Administration of a targeted cytotoxic analog of luteinizing hormone-releasing hormone inhibits growth of estrogen-independent MDA-MB-231 human breast cancers in nude mice
Authors: Kahan, Z Nagy, A Schally, AV Halmos, G Arencibia, JM Groot, K
Citation: Z. Kahan et al., Administration of a targeted cytotoxic analog of luteinizing hormone-releasing hormone inhibits growth of estrogen-independent MDA-MB-231 human breast cancers in nude mice, BREAST CANC, 59(3), 2000, pp. 255-262
High incidence of receptors for luteinizing hormone-releasing hormone (LHRH) and LHRH receptor gene expression in human prostate cancers
Authors: Halmos, G Arencibia, JM Schally, AV Davis, R Bostwick, DG
Citation: G. Halmos et al., High incidence of receptors for luteinizing hormone-releasing hormone (LHRH) and LHRH receptor gene expression in human prostate cancers, J UROL, 163(2), 2000, pp. 623-629
Inhibition of growth of MDA-MB-468 estrogen-independent human breast carcinoma by bombesin/gastrin-releasing peptide antagonists RC-3095 and RC-3940-II
Authors: Kahan, Z Sun, BD Schally, AV Arencibia, JM Cai, RZ Groot, K Halmos, G
Citation: Z. Kahan et al., Inhibition of growth of MDA-MB-468 estrogen-independent human breast carcinoma by bombesin/gastrin-releasing peptide antagonists RC-3095 and RC-3940-II, CANCER, 88(6), 2000, pp. 1384-1392
Targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 inhibits the growth of PC-82 human prostate cancer in nude mice
Authors: Koppan, M Nagy, A Schally, AV Plonowski, A Halmos, G Arencibia, JM Groot, K
Citation: M. Koppan et al., Targeted cytotoxic analog of luteinizing hormone-releasing hormone AN-207 inhibits the growth of PC-82 human prostate cancer in nude mice, PROSTATE, 38(2), 1999, pp. 151-158
Growth inhibition of experimental pancreatic cancers and sustained reduction in epidermal growth factor receptors during therapy with hormonal peptide analogs
Authors: Szepeshazi, K Halmos, G Schally, AV Arencibia, JM Groot, K Vadillo-Buenfil, M Rodriguez-Martin, E
Citation: K. Szepeshazi et al., Growth inhibition of experimental pancreatic cancers and sustained reduction in epidermal growth factor receptors during therapy with hormonal peptide analogs, J CANC RES, 125(8-9), 1999, pp. 444-452
Expression of growth hormone-releasing hormone (GHRH) messenger ribonucleic acid and the presence of biologically active GHRH in human breast, endometrial, and ovarian cancers
Authors: Kahan, Z Arencibia, JM Csernus, VJ Groot, K Kineman, RD Robinson, WR Schally, AV
Citation: Z. Kahan et al., Expression of growth hormone-releasing hormone (GHRH) messenger ribonucleic acid and the presence of biologically active GHRH in human breast, endometrial, and ovarian cancers, J CLIN END, 84(2), 1999, pp. 582-589
Complete regression of MX-1 human breast carcinoma xenografts after targeted chemotherapy with a cytotoxic analog of luteinizing hormone-releasing hormone, AN-207
Authors: Kahan, Z Nagy, A Schally, AV Halmos, G Arencibia, JM Groot, K
Citation: Z. Kahan et al., Complete regression of MX-1 human breast carcinoma xenografts after targeted chemotherapy with a cytotoxic analog of luteinizing hormone-releasing hormone, AN-207, CANCER, 85(12), 1999, pp. 2608-2615
Risultati: 1-12 |